Fisher Scientific Company L.L.C.

Fisher Scientific Company L.L.C., doing business as Fisher Scientific, is a for-profit limited liability company and wholly owned subsidiary of Thermo Electron Corporation that supplies laboratory equipment, scientific products, diagnostic test kits, chemicals, and medical supplies to federal agencies as a prime contractor operating predominantly under full-and-open competition with no set-aside designations. Headquartered in Pittsburgh, Pennsylvania, Fisher Scientific operates across primary NAICS 424210 (Medical, Dental, and Hospital Equipment and Supplies Merchant Wholesalers) and PSC 6640 (Laboratory Equipment and Supplies), with a federal award footprint dominated by volume ordering of consumable and capital equipment through Defense Logistics Agency supply contracts.

Fisher Scientific's federal customer base is heavily concentrated. The Defense Logistics Agency Troop Support Medical command accounts for approximately 85% of awards (274,078 awards, $1.13 billion combined potential value) — a concentration that reflects DLA's role as the primary federal medical supply distributor to the Department of Defense. The next tier of customers — the National Institutes of Health Office of the Director (1,266 awards, $23.6 million), the Food and Drug Administration (1,136 awards, $22.7 million), the CDC Pittsburgh (593 awards, $16.8 million), and the NIH National Institute of Environmental Health Sciences (580 awards, $8.9 million) — collectively represent less than 1% of award count but anchor meaningful research and regulatory laboratory work. The Department of the Army Medical Command rounds out the top five by potential value at $84.8 million across 257 awards. This customer concentration, driven by DLA's medical supply operations, is the dominant signal: Fisher Scientific's federal business is structurally tied to defense healthcare logistics rather than diversified civilian agency partnerships.

Vehicle position is similarly concentrated. Fisher Scientific holds positions on three large Defense Logistics Agency IDCs: SPE2DE19D0007 (112,620 task orders, $137.6 million combined potential value), SPM2DE14D7351 (102,336 task orders, $67.5 million), and SPE2DE24D0021 (54,565 task orders, $70.1 million). These three vehicles alone account for the bulk of recent ordering. Fisher Scientific also maintains positions on GSA Federal Supply Schedules V797P5497X (13,499 task orders, $30.9 million) and GS25F7087G (10,288 task orders, $78.1 million), which support civilian agency procurements. A single-award Blanket Purchase Agreement with the Indian Health Service, established May 11, 2026, carries a $650,000 ceiling through May 10, 2031 and procures laboratory supplies and equipment on an as-needed basis for IHS facilities nationwide. The recent award activity includes representative orders: a $24,999 purchase order from USDA's Animal and Plant Health Inspection Service for a KingFisher PlasmidPro Maxi Processor with installation and training (July 8, 2026); a $29,993 FDA delivery order for a hybrid multi-mode reader under GSA MAS (July 8, 2026); a $151,263 delivery order from the Shared Services Center for an Agilent Biotek Synergy Neo2 hybrid multi-mode microplate reader under GSA MAS (June 29, 2026); and a $130,000 Indian Health Service BPA call for laboratory supplies (May 15, 2026).

Recent activity reflects sustained demand. Fisher Scientific recorded 8,739 awards year-to-date in 2026 (as of July 10), following 28,571 in 2025 and 27,963 in 2024. This volume trajectory, driven primarily by DLA medical supply ordering, appears stable rather than declining, though the annualized 2026 rate is depressed by the early-year snapshot. Recompete exposure over the next twenty-four months is modest: fifty-eight awards with combined potential value of $8.6 million reach ultimate completion. The vast majority of Fisher Scientific's federal footprint consists of routine purchase orders and delivery orders for consumables and equipment on established vehicles, where recompete risk is distributed across hundreds of small transactions rather than concentrated in a handful of large contract vehicles vulnerable to competitive bid loss.

Capability portfolio centers on medical and laboratory consumables, diagnostic test kits, specialty reagents, and laboratory instrumentation. Recent awards span respiratory and infectious-disease diagnostics (OraQuick HIV test kits, BINAX NOW Streptococcus pneumoniae diagnostic strips, Sofia RSV test kits, FLU A/B Alere test kits), hematology and clinical chemistry supplies (microplate readers, washers, thermocyclers, centrifuges, blood collection tubes, hematology controls), microbiology culture media and plates (blood agar, MacConkey agar, Thayer Martin agar), laboratory reagents and buffers, and specialized equipment (incubators, freezers, cryogenic storage systems, HEPA-filtered equipment enclosures). The award detail also surfaces medical supplies such as syringes, needles, swabs, and personal protective equipment. This portfolio is commodity-like in character — high-volume, low-margin, rapid-turnaround supply to defense and civilian health agencies. The company's position as a subsidiary of Thermo Electron Corporation, a major manufacturer of scientific instrumentation and diagnostics, surfaces Thermo Fisher brand products (KingFisher processors, Agilent Biotek multi-mode readers, Thermo Scientific handheld narcotics analyzers) as core offerings alongside third-party reagents and supplies.

Sub-award and grant activity is minimal. Fisher Scientific holds only two recorded sub-award relationships in the source: a sub-award from Fluor Marine Propulsion, LLC for chemicals in support of Naval Nuclear Laboratory management (January 22, 2026), and a sub-grant from the Maine Department of Health and Human Services for cloud-based data loggers supporting the Maine Immunization Program (July 26, 2024). Federal grant work is absent from the prime footprint. This posture — nearly 100% prime contractor awards, predominantly full-and-open competitive, concentrated in high-volume medical supply logistics — positions Fisher Scientific as a vendor optimized for DLA-style transactional ordering rather than complex systems integration, research funding, or specialized defense capabilities work.